Search Results - "Legendre, C."

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome by Legendre, C.M, Licht, C, Muus, P, Greenbaum, L.A, Babu, S, Bedrosian, C, Bingham, C, Cohen, D.J, Delmas, Y, Douglas, K, Eitner, F, Feldkamp, T, Fouque, D, Furman, R.R, Gaber, O, Herthelius, M, Hourmant, M, Karpman, D, Lebranchu, Y, Mariat, C, Menne, J, Moulin, B, Nürnberger, J, Ogawa, M, Remuzzi, G, Richard, T, Sberro-Soussan, R, Severino, B, Sheerin, N.S, Trivelli, A, Zimmerhackl, L.B, Goodship, T, Loirat, C

“…This article describes the use of eculizumab in patients with atypical hemolytic–uremic syndrome. This C5 inhibitor was associated with improvement in…”
Get full text

The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology by Loupy, A., Haas, M., Solez, K., Racusen, L., Glotz, D., Seron, D., Nankivell, B. J., Colvin, R. B., Afrouzian, M., Akalin, E., Alachkar, N., Bagnasco, S., Becker, J. U., Cornell, L., Drachenberg, C., Dragun, D., Kort, H., Gibson, I. W., Kraus, E. S., Lefaucheur, C., Legendre, C., Liapis, H., Muthukumar, T., Nickeleit, V., Orandi, B., Park, W., Rabant, M., Randhawa, P., Reed, E. F., Roufosse, C., Seshan, S. V., Sis, B., Singh, H. K., Schinstock, C., Tambur, A., Zeevi, A., Mengel, M.

“…The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of…”
Get full text

Antibody‐mediated vascular rejection of kidney allograft: characterization of different kidney allograft rejection phenotypes via histology, C4d deposition and donor‐specific antibodies by Legendre, C.

Get full text

Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing by Thervet, E, Loriot, M A, Barbier, S, Buchler, M, Ficheux, M, Choukroun, G, Toupance, O, Touchard, G, Alberti, C, Le Pogamp, P, Moulin, B, Le Meur, Y, Heng, A E, Subra, J F, Beaune, P, Legendre, C

“…Retrospective studies have demonstrated that patients who are expressors of cytochrome P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a…”
Get full text

Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups by Sis, B., Mengel, M., Haas, M., Colvin, R. B., Halloran, P. F., Racusen, L. C., Solez, K., Baldwin, W. M., Bracamonte, E. R., Broecker, V., Cosio, F., Demetris, A. J., Drachenberg, C., Einecke, G., Gloor, J., Glotz, D., Kraus, E., Legendre, C., Liapis, H., Mannon, R. B., Nankivell, B. J., Nickeleit, V., Papadimitriou, J. C., Randhawa, P., Regele, H., Renaudin, K., Rodriguez, E. R., Seron, D., Seshan, S., Suthanthiran, M., Wasowska, B. A., Zachary, A., Zeevi, A.

“…The 10th Banff Conference on Allograft Pathology was held in Banff, Canada from August 9 to 14, 2009. A total of 263 transplant clinicians, pathologists,…”
Get full text

Intraplate Volcanism and Regional Geodynamics in NE Asia Revealed by Anisotropic Rayleigh‐Wave Tomography by Fan, Xingli, Chen, Qi‐Fu, Legendre, C. P., Guo, Zhen

“…Seismic structure related to the magmatic system beneath the potentially hazardous Changbaishan volcano recently becomes hotly debated. In addition, mantle…”
Get full text

Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study by Gatault, P., Kamar, N., Büchler, M., Colosio, C., Bertrand, D., Durrbach, A., Albano, L., Rivalan, J., Le Meur, Y., Essig, M., Bouvier, N., Legendre, C., Moulin, B., Heng, A.‐E., Weestel, P.‐F., Sayegh, J., Charpentier, B., Rostaing, L., Thervet, E., Lebranchu, Y.

“…The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended‐release tacrolimus (TacER)…”
Get full text

Crustal structure and upper mantle anisotropy of the Afar triple junction by Kumar, U., Legendre, C. P., Huang, B. S.

“…The Afar region is a tectonically distinct area useful for studying continental break-up and rifting. Various conflicting models have been suggested to explain…”
Get full text

European perspective on human polyomavirus infection, replication and disease in solid organ transplantation by Hirsch, H.H, Babel, N., Comoli, P., Friman, V., Ginevri, F., Jardine, A., Lautenschlager, I., Legendre, C., Midtvedt, K., Muñoz, P., Randhawa, P., Rinaldo, C.H, Wieszek, A.

“…Human polyomaviruses (HPyVs) are a growing challenge in immunocompromised patients in view of the increasing number of now 12 HPyV species and their diverse…”
Get full text

Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation by Zuber, J., Le Quintrec, M., Krid, S., Bertoye, C., Gueutin, V., Lahoche, A., Heyne, N., Ardissino, G., Chatelet, V., Noël, L.‐H., Hourmant, M., Niaudet, P., Frémeaux‐Bacchi, V., Rondeau, E., Legendre, C., Loirat, C.

“…Eculizumab (anti‐C5) has been sporadically reported as an efficient therapy for atypical hemolytic uremic syndrome (aHUS). However, the lack of series…”
Get full text

Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials by Brennan, D. C., Legendre, C., Patel, D., Mange, K., Wiland, A., McCague, K., Shihab, F. S.

“…Everolimus (EVR) in heart and renal transplant (RTx) recipients may be associated with a decreased incidence of cytomegalovirus (CMV). A detailed analysis of…”
Get full text

Long‐Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype by Pallet, N., Etienne, I., Buchler, M., Bailly, E., Hurault de Ligny, B., Choukroun, G., Colosio, C., Thierry, A., Vigneau, C., Moulin, B., Le Meur, Y., Heng, A.‐E., Legendre, C., Beaune, P., Loriot, M. A., Thervet, E.

“…Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is associated with improved achievement of target trough concentration (C0),…”
Get full text

Specificity of Histological Markers of Long‐Term CNI Nephrotoxicity in Kidney‐Transplant Recipients Under Low‐Dose Cyclosporine Therapy by Snanoudj, R., Royal, V., Elie, C., Rabant, M., Girardin, C., Morelon, E., Kreis, H., Fournet, J.‐C., Noël, L.‐H., Legendre, C.

“…The specificity of chronic histological lesions induced by calcineurin inhibitors (CNI) is often questioned, but few studies have directly compared long‐term…”
Get full text

Cyclosporine‐Induced Endoplasmic Reticulum Stress Triggers Tubular Phenotypic Changes and Death by Pallet, N., Bouvier, N., Bendjallabah, A., Rabant, M., Flinois, J. P., Hertig, A., Legendre, C., Beaune, P., Thervet, E., Anglicheau, D.

“…The molecular mechanisms by which cyclosporine induces chronic nephrotoxicity remain poorly understood. A previous transcriptomic study suggested that…”
Get full text

A shear wave velocity model of the European upper mantle from automated inversion of seismic shear and surface waveforms by Legendre, C. P., Meier, T., Lebedev, S., Friederich, W., Viereck‐Götte, L.

“…SUMMARY We present a new, S‐velocity model of the European upper mantle, constrained by inversions of seismic waveforms from broad‐band stations in Europe and…”
Get full text

Kidney Transplant Recipients Carrying the CYP3A422 Allelic Variant Have Reduced Tacrolimus Clearance and Often Reach Supratherapeutic Tacrolimus Concentrations by Pallet, N., Jannot, A.‐S., El Bahri, M., Etienne, I., Buchler, M., de Ligny, B. H., Choukroun, G., Colosio, C., Thierry, A., Vigneau, C., Moulin, B., Le Meur, Y., Heng, A.‐E., Subra, J.‐F., Legendre, C., Beaune, P., Alberti, C., Loriot, M. A., Thervet, E.

“…CYP3A4*22 is an allelic variant of the cytochrome P450 3A4 associated with a decreased activity. Carriers of this polymorphism may require reduced tacrolimus…”
Get full text

AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game by Canaud, G, Legendre, C, Terzi, F

Get full text

Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor–Intolerant Graft Recipients of Kidneys From Extended‐Criteria Donors by Le Meur, Y., Aulagnon, F., Bertrand, D., Heng, A. E., Lavaud, S., Caillard, S., Longuet, H., Sberro‐Soussan, R., Doucet, L., Grall, A., Legendre, C.

“…Transplant recipients receiving a kidney from an extended‐criteria donor (ECD) are exposed to calcineurin inhibitor (CNI) nephrotoxicity, as demonstrated by…”
Get full text

Early Low Urinary CXCL9 and CXCL10 Might Predict Immunological Quiescence in Clinically and Histologically Stable Kidney Recipients by Rabant, M., Amrouche, L., Morin, L., Bonifay, R., Lebreton, X., Aouni, L., Benon, A., Sauvaget, V., Le Vaillant, L., Aulagnon, F., Sberro, R., Snanoudj, R., Mejean, A., Legendre, C., Terzi, F., Anglicheau, D.

“…We monitored the urinary C‐X‐C motif chemokine (CXCL)9 and CXCL10 levels in 1722 urine samples from 300 consecutive kidney recipients collected during the…”
Get full text

Outcome of Subclinical Antibody‐Mediated Rejection in Kidney Transplant Recipients with Preformed Donor‐Specific Antibodies by Loupy, A., Suberbielle‐Boissel, C., Hill, G. S., Lefaucheur, C., Anglicheau, D., Zuber, J., Martinez, F., Thervet, E., Méjean, A., Charron, D., Duong van Huyen, J. P., Bruneval, P., Legendre, C., Nochy, D.

“…This study describes clinical relevance of subclinical antibody‐mediated rejection (SAMR) in a cohort of 54 DSA‐positive kidney transplant recipients receiving…”
Get full text